HEALTH SCIENCES AUTHORITY

**OCTOBER 2026**

# PRODUCT REGISTRATION SUBMISSION GUIDE

E-Submission Guide for General Medical Devices for ASEAN CSDT and IMDRF ToC based Submissions in SHARE

Revision 5

HSA Health Sciences Authority

## CONTENTS

1. INTRODUCTION ..... 3
1.1 Purpose ..... 3
1.2 Background ..... 3
1.3 Scope ..... 3
2. SUBMISSION GUIDELINES ..... 3
2.1 SHARE application form ..... 3
2.1.1 Submissions based on CSDT ..... 3
2.1.2 Submissions based on IMDRF nIVD ToC ..... 4
2.2 Submitting responses to Input request queries via SHARE ..... 4
2.3 Reference documents ..... 4
3. TABLE 1 – SUMMARY OF SUBMISSION REQUIREMENTS ..... 5

**REVISION HISTORY**

| Guideline Version (Effective Date) *[3 latest revisions]* | Revision |
|---|---|
| R3► Revision 3 (01 Mar 2024) | R3 |
| R4► Revision 4 (21 Oct 2025) | R4 |
| R5► Revision 5 (01 Oct 2026) | R5 |

**Where applicable, changes and updates made in each document revision are annotated with or within the arrow symbol "►". Deletions may not be shown.*

# 1. INTRODUCTION

## 1.1 Purpose

This document is intended to provide guidance on submission of a product registration dossier to HSA via the R4► Singapore Health Product Access and Regulatory E-System (SHARE). This guide specifies the appropriate folders in SHARE for uploading of the corresponding sections of the CSDT or IMDRF ToC dossier. ◄

## 1.2 Background

Product registration applications for medical devices are submitted online to HSA and may be compiled and prepared from the ASEAN Common Submission Dossier Template (CSDT) or the International Medical Device Regulators Forum (IMDRF) R5► Non-In Vitro Diagnostic Device Regulatory Submission Table of Contents (nIVD ToC) from the medical device manufacturer. ◄

Applications must be submitted online to HSA via SHARE. The technical dossier and supporting documents shall be submitted in softcopy in SHARE.

## 1.3 Scope

This document applies to general medical devices only.

# 2. SUBMISSION GUIDELINES

## 2.1 SHARE application form

The technical dossier and supporting documents are to be submitted under the 'Supporting Documents' section of the SHARE application form. This section of the application form comprises several folders for uploading the documents.

To facilitate review of the pre-market application, applicants shall ensure that the relevant section of the dossier and supporting documents are uploaded correctly under each folder. Document file names should also be meaningful and provide some indication of their content.

The "SHARE application form" column in TABLE 1 lists the various folders in the 'Supporting Documents' section of the SHARE application form and includes a brief description of the expected contents to be uploaded under each of the folders.

### 2.1.1 Submissions based on CSDT

Please refer to "CSDT TR-01" column of TABLE 1 to determine which sections of the CSDT are to be uploaded under each folder in SHARE.

### 2.1.2 Submissions based on IMDRF nIVD ToC

Please refer to “IMDRF nIVD ToC” column of TABLE 1 to determine which sections of the ToC are to be uploaded under each folder in SHARE.

## 2.2 Submitting responses to Input request queries via SHARE

To facilitate identification and review of information uploaded onto SHARE in response to queries raised during the evaluation process, a written response to each input request query shall be provided. If additional documents are submitted to support your response, please indicate the relevant file name(s) in your response. R4► Applicants may respond to input requests by selecting "Reply", navigating directly to the relevant section by selecting "Go to section", or consolidating their response within a separate document for formal submission to HSA. ◄

## 2.3 Reference documents

| Product Registration Submission | Document | Location |
|---|---|---|
| Based on the ASEAN CSDT | GN-17: Guidance on Preparation of a Product Registration Submission for General Medical Devices using the ASEAN CSDT<br><br>TR-01: Contents of a Product Registration Submission for General Medical Devices using the ASEAN CSDT | www.hsa.gov.sg |
| R5► Based on the nIVD ToC | IMDRF Non-In Vitro Diagnostic Device Regulatory Submission Table of Contents (nIVD ToC) ◄ | www.imdrf.org |

## 3. TABLE 1 – SUMMARY OF SUBMISSION REQUIREMENTS

**Legend:**

| | |
|---|---|
| F | Full evaluation route |
| A | Abridged evaluation route |
| E | Expedited evaluation route |
| I | Immediate registration route |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| 1 | **Letter of authorisation** | | | | | | | | | |
| | ▪ Letter of Authorisation of Registrant by the Product Owner for all the products to be registered, using the latest template as per GN-15 Annex 1 Letter of Authorisation template | R5► CH1.14 Letter of Authorisation | NA | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 2 | **Annex 2 List of Configurations** | | | | | | | | | |
| | ▪ A copy of Annex 2 for GN17 and GN18 List of Configurations, including the complete list of configurations of medical devices subject to the submission. This is to be submitted in a Microsoft Excel file. | CH1.05 Listing of Device(s) | 4.2 Device Description | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 3 | **Proof of reference agency's approval(s)** | | | | | | | | | |
| | ▪ Copies of approval letter(s) from each reference agency. For CE marked devices, the EU declaration of conformity by the product owner must be submitted, in addition to the EC certificate issued by the notified bodies. | CH1.07 Free Sale Certificate/ Certificate of Marketing authorisation | 3. Executive Summary | | ✓ | ✓ | | ✓ | ✓ | ✓ |
| 4 | R4►**Declarations** | | | | | | | | | |
| 4.1 | R4►**Declaration of Labelling** | | | | | | | | | |
| | ▪ Declaration from the product owner that labelling, packaging and IFU of the device for sale in Singapore are identical or not identical to that approved by reference agency being used as the basis for evaluation route. If not identical, please provide a description of the differences. | R5► CH2.06 Global Market History<br><br>CH2.02 General Summary of Submission | 3. Executive Summary | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 4.2 | R4►**Marketing History Declaration** | | | | | | | | | |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| | ▪ Invoice with date, proof of sale or a declaration on Marketing history as per Annex 2 of GN-15, to be completed by the local Applicant | NA | NA | | | ✓ Only required for Condition 1 | | | ✓ Only required for ECR1 | ✓ |
| 4.3 | R4► **Safety Declaration** | | | | | | | | | |
| | ▪ Safety declaration template as per Annex 3 of GN-15, to be completed by the local Applicant | NA | NA | | | ✓ | | | ✓ Only required for ECR1 | ✓ |
| 4.4 | R4►**AE and FSCA Summary or Attestation** | | | | | | | | | |
| | ▪ To include a summary of reportable adverse events (AEs) and field safety corrective actions (FSCAs) for the medical device since its first introduction on the global market, in a tabular format as per TR-01.<br>▪ For FSCAs that are 'open', provide a description of any analysis and/or corrective and preventive actions undertaken by the product owner.<br>▪ If there have been no adverse events or FSCAs to date, provide an attestation from the product owner on company letterhead, that there have been no adverse events or FSCAs since commercial introduction of the device globally. This attestation is not restricted to usage only as intended by the product owner. | R5► CH2.06 Global Market History<br><br>CH2.02 General Summary of Submission | 3. Executive Summary | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 5 | **Executive Summary** | | | | | | | | | |
| | ▪ Introductory descriptive information on the medical device, the intended use and indications for use of the device. | R5► CH2.06 Global Market History<br><br>CH2.02 General Summary of Submission | 3. Executive Summary | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | ▪ Information on the use of the device, if any, such as targeted patient population, user profile (e.g. specific trained users), specific disease status or clinical condition (e.g. continuous monitoring in critically ill patients), mode of action (e.g. absorption profile) etc. | | | | | | | | | |
| | ▪ If the medical device has any unique or novel feature or characteristic (e.g. nanotechnology, incorporates animal or microbial cells or tissues), a description must be provided. | | | | | | | | | |
| | ▪ Any high-level background information or details that the product owner wishes to highlight in relation to the device, its history or relation to other approved devices (e.g. predicate devices) or previous submissions (provides context to submission). | | | | | | | | | |
| | ▪ List of countries from HSA's reference regulatory agency jurisdictions where the medical device is marketed. | | | | | | | | | |
| | ▪ Date (accurate to MMYYYY) and country where the device was first introduced for commercial distribution, globally. | | | | | | | | | |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| | ▪ Registration status (i.e. submitted, not submitted, pending approval, rejected or withdrawn) and approved intended use and indications of the medical device in HSA's recognised reference agencies, in a tabular format as per TR-01. If device is withdrawn/ rejected by any reference agencies, reason for rejection or withdrawal is to be provided. | | | | | | | | | |
| | ▪ If the subject device is different in any way (e.g. design, commercial name, specifications, intended use and indications for use) from those approved by the reference agencies, the differences should be described. | | | | | | | | | |
| 6 | **Essential Principles Checklist and Declaration of conformity** | | | | | | | | | |
| | ▪ Essential Principles conformity checklist (EP checklist). The checklist of conformity to the Singapore Essential Principles is to be submitted. Alternatively, the checklist to EU or Australian Essential Requirements can be submitted. | R5► CH1.12.07 Declaration of Conformity<br><br>CH2.09 Essential Principles (EP) Checklist<br><br>CH2.10 Standards | 4.1. Relevant Essential Principles and Method Used to Demonstrate Conformity<br>***NOTE:*** *Refer to GN-16 Guidance on Essential Principles for Safety and Performance of Medical Devices for more details.* | ✓ | ✓ | | ✓ | ✓ | ✓ | |
| | ▪ GN-11 Declaration of Conformity (DOC). Alternatively, the EC or AU DOC can be submitted. | | | | | | | | | |
| | ▪ List the standards that have been complied with in the design and manufacture (including sterilisation) of the device, if this has not been provided in the EP checklist or DOC. | | | | | | | | | |
| 7 | R4►**Device Description** | | | | | | | | | |
| | ▪ A comprehensive description of the device including technology, functionalities, features and connectivity capabilities (e.g. wireless enabled, Bluetooth enabled, internet-connected and network-connected devices) if applicable. To include labelled pictorial representation (diagrams, photos, drawings) if applicable. | CH2.4 Device Description<br><br>CH2.5 Indications for Use and/or Intended Use and Contraindications | 4.2 Device Description | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | ▪ Risk class and applicable classification rule for the medical device according to the Regulations. | | | | | | | | | |
| | ▪ Product specifications including the version number of the software if applicable. | | | | | | | | | |
| | ▪ List of medical device accessories intended to be used in combination with the devices. Accessories that can be sold separately should be identified and listed in the Annex 2 list of configurations if intended to be supplied in Singapore. | | | | | | | | | |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| | ▪ Where safety and effectiveness data of similar or previous generation devices are used in the current submission, the following information is to be provided:<br>○ A list of such devices and specific information on the registration status of these devices with HSA are to be included (e.g. Device registration number).<br>○ A comparison, preferably in a table, of the design, specifications and intended use/indications for use between the subject device in the current submission and the comparator devices (similar and/or previous generation). To include labelled pictorial representation (diagrams, photos, drawings) where necessary. | | | | | | | | | |
| | ▪ A list of all materials in direct or indirect contact with the patient or user is to be provided. Where there are specific concerns related to the material safety (e.g. impurities or residue levels), additional information on the quality and safety of such materials may be required (e.g. conformity to relevant material standards, Certificate of Analysis). | | | | | | | | | |
| | ►R3<br>▪ Summary of software development life cycle process including processes in place to manage the various life cycle activities<br>▪ Software Requirements Specification documenting functional, performance, interface, design, developmental, and other requirements for the software. | | | | | | | | | |
| 8 | R4► **Design Verification and Validation** | | | | | | | | | |
| 8.1 | R4► **Biocompatibility** | R5► CH3.05 Non-clinical Studies<br><br>CH3.06 Non-clinical Bibliography | 4.3 Summary of Design Verification and Validation Documents | ✓ Detailed reports<br><br>► R3 Traceability Analysis linking product design requirements, design specifications, and testing requirements. Identified hazards should be tied to implementation and testing of the mitigations. | ✓ Summary | ✓ Sterilisation validation for Sterile devices only<br><br>Software verification and validation studies for standalone medical mobile applications only<br><br>Evidence to support the cybersecurity of connected medical devices | ✓ Detailed reports<br><br>► R3 Traceability Analysis linking product design requirements, design specifications, and testing requirements. Identified hazards should be tied to implementation and testing of the mitigations. | ✓ Summary | ✓ Summary | ✓ Software verification and validation studies for standalone medical mobile applications only<br><br>Evidence to support the cybersecurity of connected medical devices |
| | ▪ Studies supporting biocompatibility and assessing toxicology. If biocompatibility tests that are recommended by ISO 10993 were not performed, adequate justification must be provided. | | | | | | | | | |
| 8.2 | R4►**Sterilisation** | | | | | | | | | |
| | ▪ Sterilisation validation report, EO residuals report (if applicable), and evidence of on-going sterilisation validation | | | | | | | | | |
| 8.3 | R4► **Shelf Life** | | | | | | | | | |
| | ▪ Specify the claimed shelf life or projected useful life of the device.<br>▪ Evidence that supports the product stability and package integrity over the claimed shelf-life. If applicable, both real- | | | | | | | | | |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| | time and accelerated stability studies are to be submitted. If real-time aging has not been performed, adequate justification must be provided. | | | | | | | | | |
| 8.4 | R4► **Electrical Safety** | | | | | | | | | |
| R4► | ▪ Evidence supporting electrical safety. For example, if a device is claimed to meet the requirements of IEC 60601-1, summary test reports and/or certificates are to be submitted for verification of conformance to these standards. | | | | | | | | | |
| 8.5 | R4► **Electromagnetic Compatibility** | | | | | | | | | |
| R4► | ▪ Evidence supporting electromagnetic compatibility. For example, if a device is claimed to meet the requirements of IEC 60601-1-2, summary test reports and/or certificates are to be submitted for verification of conformance to these standards. | | | | | | | | | |
| 8.6 | R4► **Software** | | | | | | | | | |
| R4► | ▪ Specify the version of the software to be supplied.<br>***NOTE:*** *The exact software version that represents all software changes/iterations (e.g. graphic interface, functionality, bug fixes, etc.) should be provided. Software version numbering that is solely for testing or internal use are not required.*<br>▪ An overview of all verification, validation and testing performed for the software both in-house and in a simulated or actual user environment prior to final release.<br>***NOTE:*** *The version tested must be clearly identified and should match the release version of the software, otherwise to provide justification.*<br>▪ All unresolved anomalies in the release version of the software should be summarised, along with a justification for acceptability (i.e. the problem, impact on safety and effectiveness, and any plans for correction of the problems).<br>▪ Traceability Analysis linking product design requirements, design specifications, and testing requirements. Identified hazards should be tied to implementation and testing of the mitigations. | | | | | | | | | |
| 8.7 | R4► **Cybersecurity** | | | | | | | | | |
| | ▪ Evidence to support the cybersecurity of connected medical devices such as wireless enabled, Bluetooth enabled, internet-connected and network-connected devices. For example, but not limited to:<br>○ Cybersecurity vulnerabilities and risk analysis | | | | | | | | | |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| | ○ Cybersecurity control measures<br>○ Security test reports and/or evidence to verify the device cybersecurity and effectiveness of the implemented cybersecurity control measures (not applicable to IBR/ICR).<br>▪ On-going plans, processes or mechanisms for surveillance, timely detection and management of the cybersecurity-related threats during the useful life of the device, especially when a breach has been detected. | | | | | | | | | |
| 8.8 | R4► **Machine Learning** | | | | | | | | | |
| R4► | ▪ Refer to GL-04 Regulatory Guidelines for Software Medical Devices including Machine Learning-Enabled Medical Devices – A Life Cycle Approach. | | | | | | | | | |
| 8.9 | R4► **Bench Testing** | | | | | | | | | |
| | ▪ Evidence supporting the physical or mechanical properties of the subject device<br>▪ Pre-clinical animal studies (e.g. implantation) as applicable to the device | | | | | | | | | |
| 8.10 | R4► **IVD Pre-clinical Requirements** | | | | | | | | | |
| | ▪ Not applicable | | | | | | | | | |
| 8.11 | R4► **Biological Material** | | | | | | | | | |
| | ▪ Description and purpose of the biological material or derivative used in the medical device and in the manufacturing process of the medical device.<br>▪ Certificate of Suitability (CEP) for biological material that bears TSE (Transmissible Spongiform Encephalopathy) risk. If CEP is not available or not applicable, to include additional information on the evidence of proper sourcing and processing of the biological material or derivative, such as certificates that supports the safety of materials of biological origin (e.g. certificate of abattoir inspection, Certificates of Analysis)<br>▪ Risk assessment pertaining to the biological materials, which should include information on the process validation to substantiate that manufacturing and screening procedures are in place to minimise biological risks, in particular, with regard to viruses and other transmissible agents. | | | | | | | | | |
| 9 | R4► **Clinical Evaluation Report** | | | | | | | | | |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| | ▪ A clinical evaluation report reviewed and signed by an expert in the relevant field that contains an objective critical evaluation of all of the clinical data submitted in relation to the device. Clinical evidence may include clinical literature review, clinical experience (e.g. registries and post-market surveillance reports), and clinical investigation. | R5► CH4.02 Overall Clinical Evidence Summary<br>CH4.05 Real World Data (RWD)<br>CH4.06 Post-Market Surveillance Data<br>CH4.07 Other Clinical Evidence | 4.3.2. Clinical Evidence<br>***NOTE:*** *Refer to GN-20 Guidance on Clinical Evaluation for more details* | If applicable | If applicable | If applicable | ✓ | ✓ | ✓ | If applicable |
| 10 | R4► **Device Labelling** | | | | | | | | | |
| 10.1 | R4► **Device Labels** | | | | | | | | | |
| | ▪ Primary and secondary labels in their original colour for the device and its accessories as applicable.<br>▪ If representative labels are provided, variable fields on the artwork must be highlighted, and ranges of values for the variable fields should be indicated. | CH5.02 Product/Package Labels | 4.4 Device Labelling<br>***NOTE:*** *Refer to GN-23 Guidance on Labeling for Medical Devices for more details.* | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 10.2 | R4► **Instructions for Use** | | | | | | | | | |
| | ▪ Copy of the IFU to be supplied in Singapore for the device and its accessories as applicable.<br>▪ Indicate format of the IFU to be supplied with every medical device e.g. paper or electronic. | CH5.03 Package Insert/ Instructions for Use<br>CH5.04 e-labelling<br>CH5.05 Physician Labelling<br>CH5.06 Patient Labelling<br>CH5.07 Technical/Operator Manual | 4.4 Device Labelling<br>***NOTE:*** *Refer to GN-23 Guidance on Labeling for Medical Devices for more details.* | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 11 | R4► **Risk Management** | | | | | | | | | |
| | ▪ Risk analysis describing the risks identified, severity of harm and probability of occurrence including the mitigation measures. A risk management report to substantiate that all | R5► CH2.08 Risk Management | 4.5 Risk Analysis | ✓ | ✓ | | ✓ | ✓ | ✓ | |

| | SHARE Application Form - Supporting Documents | Reference technical documents | | Class B | | | Class C & D | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | IMDRF nIVD ToC | CSDT TR-01 | F | A | I | F | A | E | I |
| | known and foreseeable risks have been reasonably mitigated and the residual risks have been reduced or controlled to an acceptable level is to be submitted. | | | | | | | | | |
| 12 | R4► **Manufacturing Information (site names and addresses)** | | | | | | | | | |
| 12.1 | R4► **Site Information** | | | | | | | | | |
| | ▪ Name and address for all manufacturing and sterilisation sites (including contract manufacturers and contract sterilisers). | R5► CH6.04 General Manufacturing Information | 4.6. Manufacturer Information | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 12.2 | R4► **Quality Management System Certificates- E.g.: ISO 13485 Certificate, MDSAP Certificate, Conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169** | | | | | | | | | |
| | ▪ ISO 13485 or MDSAP certificates are to be provided for manufacturing and sterilisation sites of finished devices.<br>R4►Certification bodies for ISO 13485 must be either accredited by IAF recognised accreditation bodies or are EU MDR/IVDR Notified Bodies.<br>○ For refurbished devices, refurbishment process must be covered within the scope of the QMS certificate of the manufacturer. | CH1.06 Quality Management System, Full Quality System or Other Regulatory Certificates | 4.6. Manufacturer Information | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | ▪ For sites without ISO 13485 or MDSAP certification, comparable audit reports for the actual site e.g. US FDA Quality Systems Regulations or Japan MHLW Ordinance 169 can be submitted. | | | | | | | | | |
| 12.3 | **Manufacturing Process Flowchart** | | | | | | | | | |
| | ▪ Manufacturing process flow diagram. | R5► CH6.12 Production and service controls information | 4.6. Manufacturer Information | ✓ | | | ✓ | ✓ | ✓ | |
| 13 | **Other Documents** | | | | | | | | | |
| | ▪ Information on previous regulatory decisions (e.g. withdrawals or rejections by HSA) for the devices<br>***NOTE:*** *You may be required to provide the previous submission or registration information where necessary.* | R5► CH1.10 Pre-Submission Correspondence and Previous Regulator Interactions | NA | If applicable | If applicable | If applicable | If applicable | If applicable | If applicable | If applicable |
| | ▪ Information on any ongoing AE or FSCA reported to HSA for the subject device. | | | | | | | | | |
| | ▪ Justification for an unmet clinical need<br>***NOTE:*** *Applicable for Priority Review Scheme Route 1* | | | | | | | | | |

HEALTH SCIENCES AUTHORITY

Health Products Regulation Group
Blood Services Group
Applied Sciences Group

www.hsa.gov.sg

**Contact Information:**

Medical Devices Cluster
Health Products Regulation Group
Health Sciences Authority

www.hsa.gov.sg

HSA
Health Sciences Authority